


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently amended) A method for ~~preventing or treating dementia~~ improving memory performance in an animal, the method comprising:

~~providing~~ administering a therapeutically effective dose of a derivative of a succinate ester of general formula (I), or a stereo-isomer or a pharmaceutically acceptable salt thereof:




wherein,

R₁ and R₄ are selected from -OCH₃, -OH, -O-Glu,



R₂ and R₃ are selected from H, -OH, -O-Glu,




R₅ is selected from non-branched or branched C₁₋₆ alkyls; and

the configuration of chiral center at C-2 and C-3 are 2R3S, 2R3R, 2S3S and 2S3R respectively.


~~; and administering the succinate ester derivative to a patient.~~

2. (Currently amended) The method according to claim 1, characterized in that said compound of formula (I) is:









or a stereo-isomer or a pharmaceutically acceptable salt thereof, wherein R₅ is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl; and R₁, R₂, R₃, and R₄ are the same as that in claim 1.

3. (Currently amended) The method according to claim 2 characterized in that said compounds include:








Response to Office Action mailed February 7, 2008





1,4-bis(β-D-glucopyranosyloxybenzyl)-2-β-D-glucopyranosyl-2-isobutylmalate (dactylorhin A)
(W8);





and stereo-isomers and pharmaceutically acceptable salts thereof.

4. (Currently amended) The method according to claim 1, ~~characterized in that~~
~~said compounds include stereo-isomers and pharmaceutical acceptable salts wherein the~~
compound is a pharmaceutically acceptable salt.

5. (Currently amended) The method according to claim 1, ~~characterized in that~~
~~said dementia includes wherein the animal has Alzheimer's disease, vascular dementia, and or a~~
learning and or memory obstacle.

6. (Canceled).

7. (Canceled).

8. (Currently amended) A method for improving memory performance in an
animal comprising:

providing administering a therapeutically effective dose of an extract of
Coeloglossum viride (L.) Hartm. var. *bracteatum* (Willd.) Richter, said extract comprising
ethanol soluble compounds. ~~;~~ ~~and~~
~~utilizing the extract in the manufacture of drugs for preventing or treating~~
~~dementia.~~

9. (Currently amended) The method according to claim 8, ~~characterized in that~~
~~said dementia includes wherein the animal has Alzheimer's disease, vascular dementia, or a and~~
learning and or memory obstacle.

10. (Canceled).

11. (Canceled).

12. (Currently amended) The method according to claim 2, ~~characterized in that~~
~~said compounds include stereo-isomers and pharmaceutical acceptable salts wherein the~~
compound is a pharmaceutically acceptable salt.

13. (Currently amended) The method according to claim 3, ~~characterized in that~~
~~said compounds include stereo-isomers and pharmaceutical acceptable salts wherein the~~
compound is a pharmaceutically acceptable salt.

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (New) The method of claim 8, wherein the extract is prepared from rhizomes.

18. (New) The method of claim 8, wherein the animal is a human.

19. (New) The method of claim 18, wherein the human has Alzheimer's disease.

20. (New) The method of claim 8, further comprising administering at least one
of: scopolamine, cycloheximide, and amyloid-beta peptides.